Pyridine-containing heterocyclic compound

By developing a new compound, the blood and toxicity limitations of existing PARP inhibitors in the treatment of tumors has been solved, efficient inhibition of PARP1 and reduced hematologic toxicity, improved clinical treatment index, and provided opportunities for combined treatment .

CN118978529AInactive Publication Date: 2024-11-19SHANGHAI SINOV BIOPHARMACEUTICAL CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411060756.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing PARP inhibitors have blood and toxicity limitations when treating tumors, and are difficult to be used as a monotherapy or in combination with chemotherapy. They are not selective to PARP1, resulting in high hematological toxicity and poor clinical treatment index.

Method used

A new compound was developed to prepare inhibitors with high selectivity to PARP1 through a series of compound synthesis steps, reducing toxicity to other PARP family members, improving the efficiency of PARP1-DNA capture, and reducing hematological toxicity. and provide opportunities for combination therapy.

Benefits of technology

It has achieved efficient inhibition of PARP1, reduced hematological toxicity, improved clinical treatment index, provided possibility for combined treatment, and significantly improved tumor treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004977787580000011
    Figure BDA0004977787580000011
  • Figure BDA0004977787580000021
    Figure BDA0004977787580000021
  • Figure BDA0004977787580000031
    Figure BDA0004977787580000031
Patent Text Reader

Abstract

The invention discloses a PARP1 inhibitor compound, application of the PARP1 inhibitor compound and a pharmaceutical composition containing the PARP1 inhibitor compound. The compound has higher selectivity on PARP1 than other members of the PARP family, is an efficient PARP1-DNA trapping agent, and can be used for treating tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a class of heterocyclic compounds containing pyridine, uses thereof and pharmaceutical compositions containing the same. Background Art

[0002] Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated broad success as a class of drugs for the treatment of a variety of cancers. Approved PARP inhibitors exploit defects in DNA repair pathways to selectively target homologous recombination-deficient (HRD) tumors through PARP1 catalytic inhibition and PARP1-DNA capture. However, hematologic and other toxicities limit their use as monotherapy and in combination with chemotherapy.

[0003] Some PARP family members have been implicated in toxicity, such as the heme toxins PARP2 and the enterotoxins tankyrases (PARP5a / 5b). Recent studies have shown that the most potent PARP1 inhibitors trap PARP1 at sites of DNA breaks, generating lesions that are cytotoxic, particularly in tumor cells that lack efficient repair of DNA double-strand breaks, whereas trapping PARP2 to DNA is not required for this synthetic lethality.

[0004] We sought to discover a second-generation PARP inhibitor with greater selectivity for PARP1 over other members of the PARP family, as well as a highly efficient PARP1-DNA trap, in the hope that such a compound would offer lower hematologic toxicity and an improved clinical therapeutic index, as well as provide opportunities for combination therapy. Summary of the invention

[0005] The present invention provides the following compound or a pharmaceutically acceptable salt thereof:

[0006]

[0007] The present invention also provides use of the above-mentioned compound or a pharmaceutically acceptable salt thereof in preparing a PARP1 inhibitor, which is for treating tumors.

[0008] The present invention also provides a pharmaceutical composition, which comprises the compound shown above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0009] As used herein, the term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the present invention. DETAILED DESCRIPTION

[0010] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0011] Example 1

[0012]

[0013]

[0014] first step:

[0015] At room temperature: methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl) (2-amino-1,1'-biphenyl-2-yl) palladium (II) (0.39 g, 0.46 mmol) and tert-butyl piperazine-1-carboxylate (0.95 g, 5.11 mmol) and cesium carbonate (3.02 g, 9.30 mmol) were added to a solution (20 mL) of 5-bromopyridine-2-carboxylic acid methyl ester (1 g, 4.65 mmol), and the reaction solution was stirred at 110 degrees Celsius for 5 hours. The reaction solution was concentrated to remove the solvent, and the residue was separated and purified by silica gel column chromatography (ethyl acetate / petroleum ether) to obtain a white solid 29062A1 (0.97 g, yield 65.10%). LCMS (ESI) m / z = 322.2 [M+H] + .

[0016] Step 2:

[0017] At room temperature, a 40% aqueous solution of methylamine (10 mL) was added to a solution of compound 29062A1 (0.97 g, 3.02 mmol) in methanol (10 mL), and the reaction solution was stirred at 30 degrees Celsius for 4 hours. The reaction solution was concentrated to remove the solvent, and the residue was dissolved in EA / H2O (40 mL / 30 mL), separated, and the EA phase was washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a white solid 29062A2 (0.95 g, yield 96%). LCMS (ESI) m / z = 321.1 [M+H] + .

[0018] Step 3:

[0019] At room temperature, 4M hydrogen chloride 1,4-dioxane solution (15 mL) was added to a solution of compound 29062A2 (0.95 g, 2.97 mmol) in ethyl acetate (2 mL). The reaction solution was stirred at 25 degrees Celsius for 2 hours, and a large amount of yellow solid precipitated from the system. The reaction solution was filtered, the filter cake was washed with ethyl acetate, and dried to obtain a yellow solid 29062A3 (0.85 g, yield 97% based on two molecules of hydrochloride). LCMS (ESI) m / z = 221.1 [M+H] + .

[0020] Step 4:

[0021] At room temperature, selenium dioxide (7.92 g, 71.36 mmol) was added to a solution of 5-nitro-6-methylnicotinate (10 g, 47.58 mmol) in 1,4-dioxane (70 mL), and the reaction solution was stirred at 110 degrees Celsius for 24 hours. The reaction solution was concentrated to remove the solvent, and the residue was separated and purified by silica gel column chromatography (ethyl acetate / petroleum ether) to obtain an orange-yellow oil 29062A4 (9.70 g, yield 91%). LCMS (ESI) m / z = 225 [M+H] + .

[0022] Step 5:

[0023] Under ice bath, 60% sodium hydrogen (3.46 g, 86.60 mmol) was added in batches to the anhydrous tetrahydrofuran solution (60 mL) of compound 2-phosphonobutyric acid triethyl ester (21.82 g, 86.60 mmol). The reaction solution was stirred at room temperature for 0.5 hours and then cooled to -78 degrees Celsius. The anhydrous tetrahydrofuran solution (20 mL) of compound 29062A4 (9.70 g, 43.30 mmol) was slowly added to the reaction solution. After the addition was completed, the temperature was maintained at -78 degrees Celsius for 10 minutes. Saturated ammonium chloride was added to quench, and ethyl acetate was extracted. The organic phase was washed twice with saturated brine, concentrated to remove the solvent, and the residue was separated and purified by silica gel column chromatography (ethyl acetate / petroleum ether) to obtain an orange oil 29062A5 (10.47 g, yield 75%). LCMS (ESI) m / z = 323.1 [M + H] + .

[0024] Step 6:

[0025] At room temperature, 10% Pd / C (3 g) was added to an ethanol solution (100 mL) of compound 29062A5 (10.47 g, 32.51 mmol). The reaction mixture was stirred at room temperature for 12 hours under a hydrogen atmosphere. Pd-carbon was removed by filtration, and the filtrate was concentrated to obtain a green oil 29062A6 (crude product). LCMS (ESI) m / z = 295.1 [M+H] + .

[0026] Step 7:

[0027] At room temperature, p-toluenesulfonic acid (0.56 g, 3.25 mmol) was added to a toluene solution (100 mL) of compound 29062A6 (crude product). The reaction solution was stirred at 120 degrees Celsius for 1 hour. The solvent was removed by concentration, and the residue was separated and purified by silica gel column chromatography (ethyl acetate / petroleum ether) to obtain a white solid 29062A7 (6.95 g, two-step yield 86%). LCMS (ESI) m / z = 249.1 [M+H] + .

[0028] Step 8:

[0029] At room temperature, DDQ (2.27 g, 10.01 mmol) was added to a solution of compound 29062A7 (2.26 g, 9.10 mmol) in 1,4-dioxane (40 mL). The reaction solution was stirred at 105 degrees Celsius for 3 hours. The solvent was concentrated to remove the solvent, and a saturated sodium bicarbonate solution was added. The mixture was stirred at room temperature for 1 hour, filtered, and the filter cake was washed with water and dried to obtain a brown solid 29062A8 (1.73 g, yield 78%). LCMS (ESI) m / z = 247.1 [M+H] + .

[0030] Step 9:

[0031] In an ice bath and under argon protection, lithium aluminum tetrahydride (1M in THF, 14.06mL) was slowly added to a solution of compound 29062A8 (1.73g, 7.03mmol) in anhydrous tetrahydrofuran (20mL). The reaction solution was stirred at 0 degrees Celsius for 10 minutes. The reaction solution was quenched with saturated ammonium chloride, concentrated to remove the solvent, and the residue was separated and purified by silica gel column chromatography (DCM / MeOH) to obtain a white solid 29062A9 (0.81g, yield 56.6%). LCMS (ESI) m / z = 205.1 [M+H] + .

[0032] Step 10:

[0033] At room temperature, thionyl chloride (2.36 g, 19.85 mmol) was added to a solution of compound 29062A9 (0.81 g, 3.97 mmol) in anhydrous dichloromethane (20 mL). The reaction solution was stirred at 40 degrees Celsius for 3 hours. A large amount of solid precipitated from the system, which was filtered and alkalized with sodium bicarbonate solution. The solid was extracted with dichloromethane to obtain an off-white solid 29062A10 (0.59 g, yield 80.0%). LCMS (ESI) m / z = 223.0 [M+H] + .

[0034] Step 11:

[0035] At room temperature, anhydrous potassium carbonate (0.3 g, 2.24 mmol), 29062A3 (0.15 g, 0.50 mmol), and potassium iodide (7.46 mg, 0.044 mmol) were added to a solution of compound 29062A10 (100 mg, 0.44 mmol) in anhydrous acetonitrile (10 mL). The reaction solution was stirred at 80 degrees Celsius for 2 hours. The reaction solution was filtered and the filtrate was concentrated to obtain a crude product. The residue was separated and purified by silica gel column chromatography (DCM / MeOH) to obtain a white solid 29062A11 (0.1 g, yield 54.3%). LCMS (ESI) m / z = 407.2 [M+H] + .

[0036] Step 12:

[0037] At room temperature, m-chloroperbenzoic acid (38.12 mg, 0.22 mmol) was added to a dichloromethane solution (5 mL) of compound 29062A11 (100 mg, 0.24 mmol). The reaction solution was stirred at room temperature for 16 hours. A large amount of white solid precipitated from the system. The reaction solution was filtered to obtain a crude product, which was purified by reverse phase preparative separation to obtain a white solid EVO29062 (40.35 mg, yield 38.8%). LCMS (ESI) m / z = 423.2 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ13.23(s,1H),8.50–8.43(m,2H),8.37(d,J=2.8Hz,1H),7.96–7.82(m,2H),7.55–7.47(m,2H),4.61(s,2H),3.87 (d,J=10.5Hz,2H),3.68(h,J=11.8,11.2Hz,4H),3.46(d,J=9.3Hz,2H),2.78(d,J=4.8Hz,3H),2.45–2.36(m,2H),1.11(t,J=7.4Hz,3H).

[0038] Effect Example PARP1 in vitro test experiment

[0039] Step 1: Add 25 μL of histone solution to a 384-well plate

[0040] 1) Dilute the 5x histone mix 1:5 with 1x PBS (1 part 10x PBS buffer added to 9 parts distilled water).

[0041] 2) Add 25 μL of diluted histone solution to each well and incubate at 4°C overnight.

[0042] 3) Wash the plate three times with 100 μL PBST buffer (1x PBS containing 0.05% Tween-20) per well.

[0043] 4) Tap the plate on a clean paper towel to remove any liquid.

[0044] 5) Block the wells by adding 100 μL of Blocking Buffer 3 to each well. Incubate at room temperature for 60-90 minutes.

[0045] 6) Wash the plate three times with 100 μL PBST buffer as described above.

[0046] 7) Tap the plate on a clean paper towel to remove any liquid.

[0047] Step 2: Ribosylation reaction

[0048] 1) Prepare the master mix: N wells x (1.25 μL 10x PARP buffer + 1.25 μL 10x PARP assay mixture + 2.5 μL activated DNA + 7.5 μL distilled water). Add 12.5 μL to each well.

[0049] 2) Add 2.5 μL of inhibitor solution to each well, labeled "Test Inhibitor." For "Positive Control" and "Blank," add 2.5 μL of the same solution without inhibitor (Inhibitor Buffer).

[0050] The PARP1 Chemiluminescent Detection Kit is compatible with final DMSO concentrations up to 1%. Prepare inhibitors in 10% DMSO in water and use 2.5 μL per PARP1 reaction.

[0051] 3) Prepare 1x PARP buffer (v / v) by adding 1 part 10x PARP buffer to 9 parts distilled water.

[0052] 4) In the wells designated as "Blank", add 10 μL of 1x PARP buffer.

[0053] 5) Thaw PARP1 enzyme on ice. Calculate the amount of PARP1 required for the assay and dilute the enzyme to 1.0-2.0 ng / μL using 1x PARP buffer.

[0054] 6) Start the reaction by adding 10 μL of diluted PARP1 enzyme to the wells designated as "positive control" and "test inhibitor". Centrifuge the plate at 1000 rpm for 30 seconds and then incubate at room temperature for 60 minutes. 7) After 1 hour, discard the reaction mixture and wash the plate 3 times with 100 μL PBST buffer and tap the plate on a clean paper towel as above.

[0055] Step 3: Detection

[0056] 1) Dilute Streptavidin-HRP 1:50 in Blocking Buffer 3.

[0057] 2) Add 25 μL of diluted streptavidin-HRP to each well and incubate at room temperature (23 degrees Celsius) for 30 minutes.

[0058] 3) Wash three times with 100 μL PBST buffer as above, then tap the plate on a clean paper towel. 4) Just before use, mix 25 μL ELISA ECL Substrate A and 25 μL ELISA ECL Substrate B on ice and add 50 μL to each well.

[0059] 5) Read the chemiluminescence immediately in Envision.

[0060] The test results are shown in Table 1:

[0061] Table 1

[0062] Compound <![CDATA[PARP1 IC 50 (μM)]]> Olaparib A AZD5305* A EVO29062 A

[0063] Where A represents IC 50 <0.1μM; B represents IC 50 0.1-0.5μM; C represents IC 50 0.5-1.0μM; D represents IC 50 1.0-10.0μM.

[0064] *The structure is:

[0065]

Claims

1. A compound as shown below or a pharmaceutically acceptable salt thereof:

2. A pharmaceutical composition comprising the compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. Use of the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition, in the preparation of a PARP1 inhibitor.

4. The use as claimed in claim 3 is for treating tumors.

Citation Information

Patent Citations

  • Heterocyclic compound and application thereof

    CN117917408A

  • PARP1 inhibitors

    WO2021013735A1

  • Azaquinolinone derivative, preparation method therefor and use thereof

    WO2023232069A1